Good indepth info on ENWAVES other tecnology.. FREEZEREV.
Just how big this could be to Pharma.
EnWave Corporation Announces Major Advancement In Pharmaceutical Dehydration Technology
EnWave Corporation ("EnWave" or "the Company") recently announced that it has made a major innovation in its Radiant Energy Vacuum ("REV") pharmaceutical dehydration technology to allow for a significant reduction in the moisture content of dried vaccine products.
The new technology, called freezeREV, provides high-speed live pharmaceutical dehydration with the potential for lower energy and processing costs than conventional technology being used by the industry today. Vaccines dehydrated using freezeREV technology also had lower residual moisture content than vaccines processed using EnWave's bioREV dehydration technology. Moisture rates between 3 and 3.5 per cent, considered an acceptable industry standard, have now been achieved using the single-vial freezeREV prototype. EnWave has also filed a patent application for freezeREV covering both the technology and the processing method.
Vaccines dried to a low moisture content would be capable of withstanding longer storage at higher room temperatures without losing a significant amount of live activity ("bioactivity"), and therefore effectiveness. Production of dried live pharmaceuticals, such as vaccines, storable at room temperatures would be considered a major industry breakthrough. Dried vaccines with long shelf-life could be shipped worldwide, stored without the need for expensive, constant refrigeration, and stockpiled to protect against pandemic diseases and bioterrorism. The current "gold standard" for dehydrating many liquid pharmaceuticals is freeze drying ("lyophilization"). This process is expensive, time consuming and often results in significant loss of bioactivity during dehydration.
EnWave has been working with its collaboration partner Aridis Pharmaceuticals, LLC ("Aridis) of San Jose, California to determine the feasibility of dehydrating vaccines and antibodies using bioREV technology which rapidly dehydrates liquid pharmaceuticals at temperatures above freezing. In March 2008, the Company announced that Aridis had discovered a higher residual moisture content using bioREV than what is typically considered optimum in conventional freeze dried vaccines.
As a result of these findings, EnWave has developed freezeREV, a method to dehydrate vaccines from a frozen state capable of reducing the moisture level to industry standards. The freezeREV innovation permits microwave-assisted freeze drying and could be considered a major advancement in this area. Previous industry attempts to incorporate microwave technology into the freeze drying process have resulted in uncontrolled electrical discharge, or "arcing", which causes equipment and product damage, along with uneven drying rates. EnWave's proprietary freezeREV technology is designed to eliminate both of these problems while reducing the processing time to minutes from days for lyophilization.
"One of the advantages of freezeREV technology is that it is more compatible with freeze drying technology that is used by the industry today," explains John McNicol, President and Co-CEO of EnWave Corporation. "We are now evaluating commercial designs for a high-speed freezeREV vacuum microwave dehydrator capable of replacing a conventional freeze dryer with seamless integration into an existing plant configuration."
EnWave plans to complete dehydration testing on a number of vaccine and food culture materials using freezeREV technology to improve its process consistency, and measure recovery rates and long term shelf life. The Company is also searching for a collaboration partner with lyophilization manufacturing experience to support the commercial design and scale-up of the freezeREV equipment.
About EnWave
Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is focused on the development of new methods of dehydrating biological and food materials using Radiant Energy Vacuum technology under its bioREV, nutraREV, freezeREV and powderREV brands. REV technology combines microwave energy transfer with pressure control to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for both food products and biomaterials such as dry vaccines and antibodies. More information about EnWave is available at www.enwave.net.
SOURCE: EnWave
Like what you are reading?
Sign up for our free newsletter
Enter Your Email
I agree to the Terms and Privacy Statement.
SIGN ME UP
Newsletter Signup
Newsletter Signup
Get the latest articles from Pharmaceutical Online delivered to your inbox.
Email
I agree to the Terms and Privacy Statement.
SIGN ME UP
YOU MAY ALSO LIKE...
IMGP4743tidy.jpg
5 Common Misconceptions In Freeze Drying
Freeze drying (lyophilization) is a stabilization method that is widely used in the pharmaceutical industry for drugs, vaccines, antibodies and other biological material. Freeze drying can be a complex process to handle effectively but despite improvements in analytical and process science a number of misconceptions persist. Below we look at a selection of those we encounter most often.By Dr Laura Ciccolini, Commercial Director
Dr. Steven L. Nail, Ph.D. Of Baxter Healthcare Corporation To Present 'Advances In Process Analytical Technology In Pharmaceutical Freeze Drying' At INTERPHEX 2007
Dr. Steven L. Nail, Ph.D., Senior Baxter Research Scientist, Pharmaceutical Research and Development with Baxter Healthcare Corporation will present an in-depth course "Advances in Process Analytical Technology in Pharmaceutical Freeze-Drying" on Tuesday, April 24, 2007 at 2:00pm at INTERPHEX 2007 at the Jacob K. Javits Convention Center in New York City.
Using Spray Drying For Flu Vaccines: What Challenges Do We Need To Overcome?
When discussing the challenges of manufacturing flu vaccines, the conversation often shifts toward how manufacturers can meet the global demand each year. Currently there are some very innovative technologies aimed at addressing the challenge of manufacturing a larger supply of flu vaccines in a shorter amount of time, such as Novartis’ use of cell culture and Medicago and Fraunhofer’s use of tobacco plants. However, being able to deliver enough of a vaccine is only half the battle. It also needs to be delivered to its final destination within the appropriate temperature range. “It’s a huge misnomer for people who believe these technologies will unconstraint flu,” says Jim Robinson, VP of global technical operations, biological, and sterile products at Merck, who was involved in the manufacturing of billions of doses of flu vaccine prior to joining Merck. “The product still needs to get into a usable form and be delivered safely to the patient.”
AAPS Press Unveils Lyophilization Of Biopharmaceuticals Title
The American Association of Pharmaceutical Scientists (AAPS) is proud to announce the publication of Lyophilization of Biopharmaceuticals, the second volume of the AAPS Press series Biotechnology: Pharmaceutical Aspects....
Freeze Drying From Small Container Systems
This technical note provides an overview of freeze drying from small container systems, with a focus on the Virtis Freeze Drying System (FDS). Lyophilization from small container systems, e.g. 96 well PCR plates, is particularly attractive for highly potent API’s such as peptides or cytostatic agents. Other interesting applications include high throughput screening and long time storage of minimal amounts of samples sensitive to heat and moisture. By Margit Gieseler, GILYOS GMBH and Henning Gieseler, University Of Erlangen
Basic Cycle Development Techniques For Lyophilized Products
Technical Note: Basic Principles Of Freeze Drying
Webinars Focus On Optimization Of Freeze Drying From Lab To Production
Using Laser-Based Headspace Moisture Analysis For Rapid Nondestructive Moisture Determination Of Sterile Freeze-Dried Product
Product Characterization Services
SP Scientific Announces Sponsorship Of Lyoscopedia Freeze-Drying Seminar In March 2019
Moisture Determination of Dry Product
Advertise
Ad Specifications
Request Media Kit
Subscribe
Newsletter
Life Science Connect
BioProcess Online
Biosimilar Development
Cell & Gene
Clinical Leader
Drug Discovery
Laboratory Network
Life Science Leader Magazine
Med Device Online
Outsourced Pharma
Editorial
Archived Newsletters
Article Reprints
Editorial Submission Guidelines
Editorial Contributors
Events
CMO Leadership Awards
CRO Leadership Awards
Outsourced Pharma Events
Training
Life Science Training Institute
About Us
Contact Us
Work For Us
Copyright © 1996-2019 VertMarkets, Inc. All Rights Reserved. Terms of Use. Privacy Statement. Subscriber Request Form.
AI
